Inventors:
Anima Ghosal - Edison NJ, US
Wei Tong - New City NY, US
Swapan K. Chowdhury - Warren NJ, US
Shmuel Zbaida - East Brunswick NJ, US
Mark A. Wirth - Neshanic Station NJ, US
Kevin B. Alton - Cedar Knolls NJ, US
James E. Patrick - Aiken SC, US
Craig D. Boyle - Branchburg NJ, US
Andrew Stamford - Chatham Township NJ, US
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
C07D 473/06
A61K 31/522
A61P 9/10
A61P 9/12
US Classification:
51426334, 544271, 544272, 51426335, 51426336
Abstract:
The present invention is directed to a metabolite of a xanthine Phosphodiesterase type 5 inhibitor having the following structureFurther disclosed are methods of treating a physiological disorder, symptom or disease in a patient, comprising administering to the patient an effective amount of the above compound, wherein the physiological disorder, symptom or disease is a urogenital, cardiovascular, cerebrovascular or peripheral vascular disorder, angina pectoris, hypertension, restenosis post angioplasty, endarterectomy, stent introduction, cerebral stroke, a respiratory tract disorder such as an allergic condition associated with atopy, pulmonary hypertension, an ischemic heart disorder, impaired glucose tolerance, diabetes and its related complication, insulin resistance syndrome, hyperglycemia, polycystic ovarian syndrome, a glomerular disorder, renal insufficiency, nephritis, a tubular interstitial disorder, an autoimmune disorder, glaucoma, intestinal motility, cachexia or cancer.
